WO2005100606A3 - Gene expression markers for predicting response to chemotherapy - Google Patents

Gene expression markers for predicting response to chemotherapy Download PDF

Info

Publication number
WO2005100606A3
WO2005100606A3 PCT/US2005/011760 US2005011760W WO2005100606A3 WO 2005100606 A3 WO2005100606 A3 WO 2005100606A3 US 2005011760 W US2005011760 W US 2005011760W WO 2005100606 A3 WO2005100606 A3 WO 2005100606A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemotherapy
gene expression
predicting response
expression markers
provides
Prior art date
Application number
PCT/US2005/011760
Other languages
French (fr)
Other versions
WO2005100606A2 (en
Inventor
Joffre B Baker
Steven Shak
Luca Gianni
Original Assignee
Genomic Health Inc
Joffre B Baker
Steven Shak
Luca Gianni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc, Joffre B Baker, Steven Shak, Luca Gianni filed Critical Genomic Health Inc
Priority to CA2563074A priority Critical patent/CA2563074C/en
Priority to AU2005233593A priority patent/AU2005233593B2/en
Priority to JP2007507495A priority patent/JP5813908B2/en
Priority to EP05735478A priority patent/EP1737980A2/en
Publication of WO2005100606A2 publication Critical patent/WO2005100606A2/en
Publication of WO2005100606A3 publication Critical patent/WO2005100606A3/en
Priority to IL178508A priority patent/IL178508A/en
Priority to AU2010241525A priority patent/AU2010241525B2/en
Priority to IL214995A priority patent/IL214995A/en
Priority to IL214994A priority patent/IL214994A/en
Priority to IL244249A priority patent/IL244249A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay

Abstract

The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.
PCT/US2005/011760 2004-04-09 2005-04-07 Gene expression markers for predicting response to chemotherapy WO2005100606A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2563074A CA2563074C (en) 2004-04-09 2005-04-07 Gene expression markers for predicting response to chemotherapy
AU2005233593A AU2005233593B2 (en) 2004-04-09 2005-04-07 Gene expression markers for predicting response to chemotherapy
JP2007507495A JP5813908B2 (en) 2004-04-09 2005-04-07 Gene expression markers to predict response to chemotherapeutic agents
EP05735478A EP1737980A2 (en) 2004-04-09 2005-04-07 Gene expression markers for predicting response to chemotherapy
IL178508A IL178508A (en) 2004-04-09 2006-10-05 Gene expression markers for predicting response to chemotherapy
AU2010241525A AU2010241525B2 (en) 2004-04-09 2010-11-18 Gene expression markers for predicting response to chemotherapy
IL214995A IL214995A (en) 2004-04-09 2011-09-06 Gene expression markers for predicting response to chemotherapy
IL214994A IL214994A (en) 2004-04-09 2011-09-06 Gene expression markers for predicting response to chemotherapy
IL244249A IL244249A (en) 2004-04-09 2016-02-23 Gene expression markers for predicting response to chemotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56103504P 2004-04-09 2004-04-09
US60/561,035 2004-04-09

Publications (2)

Publication Number Publication Date
WO2005100606A2 WO2005100606A2 (en) 2005-10-27
WO2005100606A3 true WO2005100606A3 (en) 2006-06-22

Family

ID=34981928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011760 WO2005100606A2 (en) 2004-04-09 2005-04-07 Gene expression markers for predicting response to chemotherapy

Country Status (10)

Country Link
US (2) US7871769B2 (en)
EP (4) EP2270232A1 (en)
JP (3) JP5813908B2 (en)
AU (2) AU2005233593B2 (en)
CA (2) CA2563074C (en)
DK (1) DK2163650T3 (en)
ES (2) ES2636470T3 (en)
HK (1) HK1217737A1 (en)
IL (4) IL178508A (en)
WO (1) WO2005100606A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2486265T3 (en) * 2002-03-13 2014-08-18 Genomic Health, Inc. Obtaining gene expression profile in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2488845T5 (en) 2003-06-24 2017-07-11 Genomic Health, Inc. Prediction of the probability of cancer recurrence
WO2005100606A2 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
ES2384107T3 (en) * 2004-11-05 2012-06-29 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and treatment response prediction
CA3061785A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP2395109A1 (en) * 2004-12-08 2011-12-14 Aventis Pharmaceuticals Inc. Method for measuring resistance or sensitivity to docetaxel
US8133692B2 (en) * 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
EP1937837A2 (en) * 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1960551A2 (en) * 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007084992A2 (en) * 2006-01-19 2007-07-26 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US20100113299A1 (en) * 2008-10-14 2010-05-06 Von Hoff Daniel D Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
JP2008017832A (en) * 2006-06-13 2008-01-31 Sysmex Corp Method for judging metastasis of cancer and device for the same
WO2008073177A2 (en) * 2006-09-21 2008-06-19 Nuclea Biomarkers, Llc Expression profiles associated with irinotecan treatment
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
WO2008110624A2 (en) * 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano-Bicocca Sirna-mediated silencing of genes for treating chemotherapeutic drug-resistant epithelial tumors
US20090258795A1 (en) * 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
EP2191020A2 (en) * 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
JP2009050189A (en) * 2007-08-24 2009-03-12 Sumitomo Bakelite Co Ltd Method for predicting effectiveness of anti-cancer agent
CA2699385A1 (en) * 2007-09-14 2009-03-19 Ventana Medical Systems, Inc. Prostate cancer biomarkers
JP5303132B2 (en) * 2007-09-20 2013-10-02 シスメックス株式会社 Method and apparatus for determining the presence or absence of cancer cells
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
BRPI0820707A2 (en) 2007-11-07 2015-06-16 Genentech Inc Methods and composition for assessing B cell lymphoma responsiveness for anti-cd40 antibody treatment
WO2009137664A1 (en) * 2008-05-07 2009-11-12 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of bcl-2 family and uses thereof
US20090311702A1 (en) 2008-05-12 2009-12-17 Steve Shak Tests to predict responsiveness of cancer patients to chemotherapy treatment options
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
EP2297359B1 (en) 2008-05-30 2013-11-13 The University of North Carolina at Chapel Hill Gene expression profiles to predict breast cancer outcomes
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
US9670546B2 (en) 2008-07-15 2017-06-06 Epigenomics Ag Methods and nucleic acids for analyses of cell proliferative disorders
KR100996994B1 (en) * 2008-08-18 2010-11-25 울산대학교 산학협력단 Method for diagnosis of post-operative recurrence in patients with hepatocellular carcinoma
JP2012500631A (en) * 2008-08-20 2012-01-12 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド， ア ボディー コーポレイト Markers for assessing cancer susceptibility to IGF-1R treatment
JP2010057486A (en) * 2008-09-02 2010-03-18 Sysmex Corp Method for predicting response of cancer patient to chemotherapy
EP2318552B1 (en) 2008-09-05 2016-11-23 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
EP2373809A1 (en) * 2008-12-10 2011-10-12 Ipsogen Methods for identifying erbb2 alteration in tumors
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
WO2010091296A2 (en) * 2009-02-06 2010-08-12 The Regents Of The University Of California Emx2 in cancer diagnosis and prognosis
US8972899B2 (en) 2009-02-10 2015-03-03 Ayasdi, Inc. Systems and methods for visualization of data analysis
AU2010236168B2 (en) * 2009-04-18 2015-08-13 Genentech, Inc. Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
SG181806A1 (en) 2010-01-11 2012-07-30 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CN103237901B (en) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 For treating the biomarker of diagnosis
BR112012025593A2 (en) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings circulating biomarkers for disease
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
EP2588864A1 (en) * 2010-07-02 2013-05-08 Topogen Inc. Method for diagnosis of bladder cancer and related kits
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012009347A2 (en) * 2010-07-12 2012-01-19 Opko Curna Llc Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
ES2925983T3 (en) 2010-07-27 2022-10-20 Genomic Health Inc Method for using gene expression to determine prostate cancer prognosis
SG187045A1 (en) 2010-08-13 2013-02-28 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
CA2810931C (en) 2010-09-24 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
PT2619576T (en) * 2010-09-24 2020-09-14 Niels Grabe Means and methods for the prediction of treatment response of a cancer patient
JP5828446B2 (en) * 2011-02-10 2015-12-09 国立大学法人秋田大学 Radiosensitive marker for squamous cell carcinoma tissue
CA2742342A1 (en) * 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
CA2835179A1 (en) * 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
US10260097B2 (en) * 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
WO2012174203A2 (en) * 2011-06-14 2012-12-20 Anthony Albino Methods and kits for the detection and treatment of recurring prostate cancer
WO2013050998A1 (en) * 2011-10-04 2013-04-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cd247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
EP2766836A4 (en) * 2011-10-10 2015-07-15 Ayasdi Inc Systems and methods for mapping new patient information to historic outcomes for treatment assistance
CA2857505A1 (en) * 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2794924B1 (en) 2011-12-22 2019-02-06 Baylor Research Institute Identification of mirna signatures in human colorectal cancer
WO2013109690A1 (en) * 2012-01-17 2013-07-25 Myriad Genetics, Inc. Breast cancer prognosis signatures
EP3179393B1 (en) 2012-01-31 2020-07-08 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
FR2987446B1 (en) * 2012-02-28 2016-01-01 Univ Nice Sophia Antipolis DIAGNOSTIC TEST FOR RESISTANCE TO AZACITIDINE
WO2013170174A1 (en) * 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US11035005B2 (en) 2012-08-16 2021-06-15 Decipher Biosciences, Inc. Cancer diagnostics using biomarkers
ES2938766T3 (en) 2012-11-16 2023-04-14 Myriad Genetics Inc Gene signatures for cancer prognosis
WO2014081953A1 (en) 2012-11-21 2014-05-30 Richard David J Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
WO2014085653A1 (en) * 2012-11-30 2014-06-05 Celera Corporation Multi-gene signatures for predicting response to chemotherapy or risk of metastasis for breast cancer
SG11201504023SA (en) 2012-12-03 2015-06-29 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US10240206B2 (en) * 2013-02-01 2019-03-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Biomarkers and methods for predicting benefit of adjuvant chemotherapy
US10041125B2 (en) 2013-03-15 2018-08-07 Janssen Pharmaceutica Nv Assay for predictive biomarkers
JP2016521979A (en) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド Gene expression profiling algorithm for calculating recurrence score for patients with kidney cancer
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
MX2016013910A (en) * 2014-04-24 2017-01-11 Pfizer Cancer treatment.
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CN104004844A (en) * 2014-05-28 2014-08-27 杭州美中疾病基因研究院有限公司 Kit for jointly detecting breast cancer 21 genes and preparation method of kit
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
FI3198035T3 (en) * 2014-09-26 2023-01-31 Methods for predicting drug responsiveness
BR112017007962A2 (en) 2014-10-24 2018-01-23 Koninklijke Philips Nv method implemented by computer, device, storage media, computer program, kit, and kit use
AU2015334841B2 (en) * 2014-10-24 2022-02-03 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CA2974240A1 (en) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
JP2018507470A (en) 2015-01-20 2018-03-15 ナントミクス，エルエルシー System and method for predicting response to chemotherapy for high-grade bladder cancer
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
CA3008002A1 (en) * 2015-12-10 2017-06-15 Nantomics, Llc Integrated analysis to determine prognosis after treatment for primary breast cancer
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11746381B2 (en) 2017-03-10 2023-09-05 Cancer Diagnostics Research Innvovations, LLC Methods for diagnosing and treating gastric cancer using miRNA expression
CA3058018A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
RU2675236C1 (en) * 2018-02-22 2018-12-18 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method for predicting development of metastases in patients with breast cancer
CN112601552A (en) * 2018-07-12 2021-04-02 科尔沃斯制药股份有限公司 Methods for detecting and treating cancers with adenosine pathway activation
US20220357328A1 (en) * 2019-09-09 2022-11-10 Oaklabs Gmbh Superior biomarker signature to predict the response of a breast cancer patient to chemotherapy
CN111184865B (en) * 2020-03-09 2021-11-16 复旦大学附属金山医院 Application of STAT1 in treatment of paclitaxel-resistant epithelial ovarian cancer
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070085A2 (en) * 1999-05-14 2000-11-23 Theragen Molekularmedizinische Informationssysteme Ag Method for detecting the effect of different chemotherapeutic agents and/or radiation therapy in malignant diseases
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
NZ323795A (en) * 1995-12-18 2000-01-28 Sugen Inc Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) * 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
CA2271783C (en) * 1996-11-20 2013-04-16 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) * 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO1999064626A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
AU2342900A (en) 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
WO2000050595A2 (en) 1999-02-25 2000-08-31 Ivan Gout Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
CA2391805A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
AU2001232485A1 (en) * 2000-01-13 2001-07-24 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US6618679B2 (en) * 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001070979A2 (en) 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
AU2001251086A1 (en) * 2000-03-31 2001-10-15 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001280008A1 (en) * 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
AU2001278076A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
WO2002031209A2 (en) 2000-10-13 2002-04-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Genes related to development of refractory prostate cancer
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7776518B2 (en) * 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
JP4368110B2 (en) * 2001-01-12 2009-11-18 エール ユニヴァーシティ Detection of survivin in biological fluids of cancer patients
MXPA03006617A (en) 2001-01-24 2004-12-02 Protein Design Labs Inc Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer.
WO2002070741A2 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
EP1373896A2 (en) 2001-03-12 2004-01-02 MonoGen, Inc. Cell-based detection and differentiation of disease states
US20030077582A1 (en) * 2001-03-27 2003-04-24 Wen-Lin Kuo Methods for diagnosing and monitoring malignancies by screeining gene copy numbers
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
EP1410011B1 (en) 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
CN102402650A (en) * 2001-11-09 2012-04-04 生命技术公司 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US20030124130A1 (en) * 2002-01-02 2003-07-03 Brown Robert E. Proteomic analysis of tumors for development of consultative report of therapeutic options
AU2003201741A1 (en) * 2002-01-09 2003-07-24 Yusuke Nakamura Cancer profiles
US7704700B2 (en) * 2002-02-12 2010-04-27 Burnham Institute For Medical Research Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
ES2486265T3 (en) * 2002-03-13 2014-08-18 Genomic Health, Inc. Obtaining gene expression profile in biopsied tumor tissues
US20050216961A1 (en) 2002-03-28 2005-09-29 Delaney Allen D Cancer associated protein kinases and their uses
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
EP1365034A3 (en) 2002-05-21 2004-02-18 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004074518A1 (en) 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
JP2007507222A (en) 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド Gene expression markers for predicting response to chemotherapy
ES2488845T5 (en) 2003-06-24 2017-07-11 Genomic Health, Inc. Prediction of the probability of cancer recurrence
CA2531967C (en) * 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005100606A2 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1747292B1 (en) 2004-05-07 2015-07-08 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
CA2569202A1 (en) * 2004-05-28 2005-12-15 Board Of Regents, The University Of Texas System Multigene predictors of response to chemotherapy
CA3061785A1 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
ES2384107T3 (en) 2004-11-05 2012-06-29 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and treatment response prediction
AU2006254834B2 (en) 2005-06-08 2012-09-20 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
EP1974058B1 (en) 2006-01-11 2014-06-11 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20090258795A1 (en) 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2191020A2 (en) 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
WO2009114836A1 (en) 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US20090311702A1 (en) 2008-05-12 2009-12-17 Steve Shak Tests to predict responsiveness of cancer patients to chemotherapy treatment options
WO2010056931A1 (en) 2008-11-14 2010-05-20 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
EP2370813A4 (en) 2008-12-04 2012-05-23 Univ California Materials and methods for determining diagnosis and prognosis of prostate cancer
JP2012525159A (en) 2009-05-01 2012-10-22 ジェノミック ヘルス， インコーポレイテッド Gene expression profile algorithms and trials in colorectal cancer recurrence and possible response to chemotherapy
DK2504451T3 (en) 2009-11-23 2019-08-05 Genomic Health Inc Methods for predicting the clinical course of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070085A2 (en) * 1999-05-14 2000-11-23 Theragen Molekularmedizinische Informationssysteme Ag Method for detecting the effect of different chemotherapeutic agents and/or radiation therapy in malignant diseases
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Affymetrix GeneChip Human Genome U95 Set HG-U95A", GENBANK GEO, 11 March 2002 (2002-03-11), XP002293987 *
BERTUCCI F ET AL: "GENE EXPRESSION PROFILES OF POOR-PROGNOSIS PRIMARY BREAST CANCER CORRELATE WITH SURVIVAL", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 8, 15 April 2002 (2002-04-15), pages 863 - 872, XP001146244, ISSN: 0964-6906 *
JOHNSON SANDRA A S ET AL: "Increased expression of TATA-binding protein, the central transcription factor, can contribute to oncogenesis.", MOLECULAR AND CELLULAR BIOLOGY, vol. 23, no. 9, May 2003 (2003-05-01), pages 3043 - 3051, XP002350333, ISSN: 0270-7306 *
MUSS H B ET AL: "C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST CANCER", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 330, no. 18, 5 May 1994 (1994-05-05), pages 1260 - 1266, XP009040793, ISSN: 1533-4406 *
RING A E ET AL: "PREDICTORS OF RESPONSE TO SYSTEMIC THERAPY IN BREAST CANCER", FORUM, GENOVA, IT, vol. 12, no. 1, 2002, pages 19 - 32, XP009012703, ISSN: 1121-8142 *
SORLIE T ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483, ISSN: 0027-8424 *
SOTIRIOU C ET AL: "Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 4, no. 3, 2002, pages R3 - 1, XP002318508, ISSN: 1465-5411 *
STEARNS V ET AL: "A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 1, January 2003 (2003-01-01), pages 124 - 133, XP002318509, ISSN: 1078-0432 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Also Published As

Publication number Publication date
US20050260646A1 (en) 2005-11-24
CA2563074A1 (en) 2005-10-27
IL214995A0 (en) 2011-10-31
JP6130726B2 (en) 2017-05-17
EP2270232A1 (en) 2011-01-05
HK1217737A1 (en) 2017-01-20
EP1737980A2 (en) 2007-01-03
IL244249A (en) 2017-04-30
IL244249A0 (en) 2016-04-21
IL214994A0 (en) 2011-10-31
IL214994A (en) 2013-02-28
ES2550614T3 (en) 2015-11-11
AU2005233593B2 (en) 2010-08-26
AU2010241525A1 (en) 2010-12-09
EP2163650B1 (en) 2015-08-05
IL214995A (en) 2016-03-31
DK2163650T3 (en) 2015-11-02
CA2848463A1 (en) 2005-10-27
EP2163650A1 (en) 2010-03-17
IL178508A (en) 2011-11-30
US9605318B2 (en) 2017-03-28
ES2636470T3 (en) 2017-10-05
US7871769B2 (en) 2011-01-18
JP2013176388A (en) 2013-09-09
AU2005233593A1 (en) 2005-10-27
JP2007532113A (en) 2007-11-15
JP5813908B2 (en) 2015-11-17
AU2010241525B2 (en) 2011-07-21
JP2016041071A (en) 2016-03-31
EP2947160A1 (en) 2015-11-25
EP2947160B1 (en) 2017-07-12
CA2563074C (en) 2014-05-20
WO2005100606A2 (en) 2005-10-27
IL178508A0 (en) 2007-02-11
JP6190434B2 (en) 2017-08-30
US20110129833A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
WO2005100606A3 (en) Gene expression markers for predicting response to chemotherapy
WO2004111603A3 (en) Gene expression markers for predicting response to chemotherapy
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
WO2007067500A3 (en) Predictors of patient response to treatment with egfr inhibitors
WO2007084992A3 (en) Prognosis and therapy predictive markers and methods of use
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
WO2006110264A3 (en) Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
EP2021534A4 (en) Assessment and reduction of risk of graft-versus-host disease
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
WO2006037462A3 (en) Cancer markers
EP2235174A4 (en) Thermophilic and thermoacidophilic biopolymer- degrading genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods
WO2009073478A3 (en) Tle3 as a marker for chemotherapy
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2007058968A3 (en) Gene expression profiles and methods of use
IL184075A0 (en) Universal reference standard for normalization of microarray gene expression profiling data
WO2007012811A3 (en) Prostate stem cell markers
WO2007067813A3 (en) Methods and compositions for assessing alterations in gene expression patterns in clinically normal tissues obtained from heterozygous carriers of mutant genes associated with cancer and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2563074

Country of ref document: CA

Ref document number: 178508

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007507495

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005233593

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 2005233593

Country of ref document: AU

Date of ref document: 20050407

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005233593

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067023413

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005735478

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005735478

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067023413

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 244249

Country of ref document: IL